Werner Brammer, MD
Family Medicine · Bath, NYNPI 1710921648
Payments from drug & device makers
Across 171 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$491
- Lilly USA, LLC$356
- AstraZeneca$320
- Pfizer$293
- Novo Nordisk$184
- Abbott$161
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,306100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $491 |
| Lilly USA, LLC | 20 | $356 |
| AstraZeneca | 19 | $320 |
| Pfizer | 16 | $293 |
| Novo Nordisk | 9 | $184 |
| Abbott | 5 | $161 |
| Boehringer Ingelheim | 8 | $158 |
| Merck | 7 | $141 |
| Exact Sciences | 5 | $124 |
| GSK | 7 | $123 |
| Supernus Pharmaceuticals, Inc. | 5 | $107 |
| Johnson & Johnson | 6 | $103 |
| Sanofi-aventis U.S. LLC | 6 | $99 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $75 |
| Corcept Therapeutics | 3 | $52 |
| Bayer | 2 | $46 |
| Bardy Diagnostics, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Inogen, Inc. | 2 | $34 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| Novartis | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Astellas Pharma US Inc | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Advanced Oxygen Therapy Inc. | 1 | $10 |
How this compares
$3,321 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 81 | $89,302 |
| EliquisApixaban | 76 | $71,578 |
| JardianceEmpagliflozin | 59 | $69,011 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 322 | $66,483 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 221 | $64,940 |
| JanuviaSitagliptin Phosphate | 45 | $54,600 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 178 | $54,146 |
| TrulicityDulaglutide | 35 | $52,715 |
| OzempicSemaglutide | 41 | $49,457 |
| RybelsusSemaglutide | 16 | $36,336 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $35,426 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $28,657 |
| Nurtec OdtRimegepant Sulfate | 18 | $22,652 |
| FarxigaDapagliflozin Propanediol | 26 | $19,184 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $13,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKShingrix, Arexvy, Trelegy Ellipta, Anoro Ellipta | $123 | $180,453613 claims |
| PfizerEliquis, Abrysvo, Nurtec Odt | $293 | $148,376272 claims |
| Johnson & JohnsonXarelto | $103 | $89,30281 claims |
| Novo NordiskOzempic, Rybelsus | $184 | $85,79357 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $158 | $80,49276 claims |
| MerckJanuvia | $141 | $54,60045 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $320 | $54,55979 claims |
| Lilly USA, LLCTrulicity | $356 | $52,71535 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $11,51414 claims |
| AbbVieLinzess, Synthroid | $491 | $10,12847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Bath
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.